Editor's Correspondence
November 23, 1998

Treating Helicobacter pylori

Author Affiliations

Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998

Arch Intern Med. 1998;158(21):2396-2398. doi:

In reply

The letter from Hunt and Howden regarding our review1 illustrates the rapidly changing field of eradication therapy for Helicobacter pylori. Unfortunately, most of their comments are based on data published in abstract form after our paper was submitted for publication.

We agree that dual therapy is not an appropriate first-line treatment for H pylori infection and in our review we do not make that assertion. Instead, our intention was to alert the clinician to the suboptimal eradication rates of dual therapy compared with the superior triple and quadruple therapies, especially since 2 of the therapies listed have been approved by the Food and Drug Administration (ranitidine–bismuth citrate combination drug and clarithromycin and omeprazole-clarithromycin regimens), which may give clinicians a false sense of security.

First Page Preview View Large
First page PDF preview
First page PDF preview